| 0.3446 -0.041 (-10.73%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.27 | 1-year : | 1.83 |
| Resists | First : | 1.09 | Second : | 1.57 |
| Pivot price | 0.52 |
|||
| Supports | First : | 0.31 | Second : | 0.26 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.6 |
| MA(100) : | 1.24 |
MA(250) : | 1.9 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 3.2 |
D(3) : | 2.7 |
| RSI | RSI(14): 20.7 |
|||
| 52-week | High : | 5.3 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VIVS ] has closed above bottom band by 24.3%. Bollinger Bands are 91.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.42 - 0.42 | 0.42 - 0.42 |
| Low: | 0.32 - 0.32 | 0.32 - 0.32 |
| Close: | 0.34 - 0.34 | 0.34 - 0.35 |
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Mon, 27 Jul 2026
VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mon, 27 Jul 2026
VivoSim Labs, Inc. Revenue Breakdown – NASDAQ:VIVS - TradingView
Fri, 24 Jul 2026
VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Tue, 21 Jul 2026
Two Chinese firms place VivoSim's first paid mainland orders - Stock Titan
Thu, 16 Jul 2026
VivoSim Announces Pricing of $4.0 Million Private Placement - GlobeNewswire
Wed, 15 Jul 2026
Why Vivosim Labs Shares Are Rocketing on Wednesday? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 3.18e+006 (%) |
| Held by Institutions | 9.3 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.127e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 967.5 % |
| Return on Equity (ttm) | -65.2 % |
| Qtrly Rev. Growth | 131000 % |
| Gross Profit (p.s.) | -15.43 |
| Sales Per Share | -210.54 |
| EBITDA (p.s.) | -2.9e+006 |
| Qtrly Earnings Growth | -5.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.28 |
| Dividend | 0 |
| Forward Dividend | 48730 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|